Atossa Therapeutics Inc. (ATOS)
Atossa Therapeutics Inc. (ATOS) Stock Price, Analysis & Data
| Bid | 1.7 |
| Market Cap | 23.05M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -37.71M |
| Beta | n/a |
| EPS (ttm) | -4.34 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.53 |
| P/B (ttm) | 0.86 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 2.96 |
| Volume | 19,365 |
| Avg. Volume (20D) | 152,562 |
| Open | 2.32 |
| Previous Close | 2.36 |
| Day's Range | 2.27 - 2.34 |
| 52-Week Range | 1.70 - 19.35 |
| Analyst | Strong Buy |
| Price Target | 22 (852.38%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ATOS
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was ...
Financial Performance
In 2025, Atossa Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -34.77M, an increase of 36.33%.
Financial StatementsAnalyst Forecast
According to 3 analyst ratings, the average rating for ATOS stock is "Strong Buy". The 12-month stock price forecast is 22, which is upside of 852.38% from the latest price.
Stock Forecasts
